제테마

216080KOSDAQ의료용품 및 기타 의약 관련제품 제조업

46.1 / 100

Reference Date: 2026-04-13

Financial Score14.0 / 40

News Sentiment18.1 / 25

Momentum4.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, PBR raises overvaluation concerns. Plunged 15.2% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Jetema develops and manufactures biopharmaceuticals based on hyaluronic acid fillers and botulinum toxin, as well as tissue sutures and lifting threads, expanding into both aesthetic and therapeutic markets. Key products like Jetema Dermal Toxin, which received domestic approval in 2024, are driving growth, with global expansion accelerated through licensing agreements with partners in Brazil, China, and Thailand.

Number of Employees

244people

Average Salary

4.5M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 19.894.0Point

PBR

4.21Industry Average 1.620.0Point

2.6x industry avg (risky)

ROE

-10.91Industry Average -4.893.5Point

2.2x industry avg (excellent)

Debt Ratio

92.88Industry Average 8.880.0Point

10.5x industry avg (risky)

Trend 2023~20256.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲14.5% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲24.5% (2-year basis)

ROE Trend

1.0 / 4

Avg ROE 2.1% (declining, 3yr)

Detailed News Sentiment

4 totalPositive 3Neutral 0Negative 0Average Sentiment Score 80

Positive
[클릭e종목]“제테마, 수출 확대·품목 다변화에 미국 진출까지”
제테마는 한미약품과 MOU를 체결하여 관절치료제 히알루마를 미용 용도로 변경한 스킨부스터 리바인의 미국 판매권을 얻어 수출 확대 및 품목 다변화를 추진하고 있습니다.
Positive
제테마, '7조 규모' 중국 톡신 시장 진출 속도 낸다
제테마는 중국 보툴리눔 톡신 시장 진출을 위한 임상 3상의 '데이터락'을 완료하며 상업화에 속도를 내고 있습니다.
Positive
제테마 “한미약품 손잡고 연내 국내 최초 미국 스킨부스터 시장 진출.....
제테마는 한미약품과 손잡고 연내 국내 기업 최초로 미국 스킨부스터 시장에 진출하여 2.5조 규모의 블루오션을 선점할 계획입니다.

Detailed Momentum

52-week position3.0Point

52w lower range (35%)

Current 7,360Won52-week high 10,89052-week low 5,400

1-month return0.0Point

1m -15.21% (strong drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

13 totalPositive 0Neutral 13Negative 0

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-08
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-08
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-08
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-03
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-03